Teclistamab plus Nirogacestat in RRMM: The MAJESTEC-2 Study

Opinion
Video

Drs Luciano Costa and Binod Dhakal discuss combining bispecific antibodies with gamma secretase inhibitors for the treatment of relapsed/refractory multiple myeloma, but trials show limited benefit and added toxicity; more promising are combinations with immunomodulators like isatuximab.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
Related Content